Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Mar 9, 2018

Keywords

ClinConnect Summary

This clinical trial is focused on developing a new treatment for men who have experienced serious damage to the tissues in their penis, often due to trauma or other medical issues. The study will test a bioengineered solution made from the patient's own cells and tissues to help repair and restore normal function. Researchers will take small samples of the patient’s cells, grow them in a lab, and use them to create custom tissue constructs to repair the damaged areas.

To participate, men aged 18 to 60 with specific types of penile deformities that have been stable for at least six months may qualify. Participants should have already tried other treatments without success. They will need to provide written consent and attend all follow-up visits. It’s important to note that individuals with certain medical conditions, such as untreated infections or serious heart problems, will not be eligible. This trial is currently not recruiting participants, but it represents an innovative approach to addressing complex penile issues.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Males aged 18-60 years.
• • 2. Acquired structural abnormalities of the corpora cavernosum secondary to trauma, infection, inflammation, or fibromatosis. These abnormalities will be diagnosed by clinical examination, and/or ultrasound, and/or computerized tomography.
• • 3. Stable abnormalities - at least 6 months with no pain or changes in deformity.
• • 4. At least one failed attempt at management by conventional approaches at least 6 months prior to enrollment
• • 5. Deformities less than 5 cm in length.
• • 6. Written informed consent obtained prior to participation in the study.
• • 7. Patients must be available for all follow up visits.
• • 8. Ability to speak English.
• Exclusion Criteria:
• • 1. Presence of untreated or incompletely treated urinary tract infection at the time of biopsy.
• • 2. Uncontrolled bleeding disorder or patients with a platelet count less than 50,000, hemophilia or patients routinely receiving blood products for bleeding disorders.
• • 3. Serum creatinine \> 2.0 mg/dl or evidence of progressive renal disease.
• • 4. ALT or AST value \>1.5 times the upper limit of normal.
• • 5. Albumin \< 3.0 g/dL.
• • 6. Serum direct bilirubin \>0.3 mg/dL OR total bilirubin \> 1.4 mg/dL
• • 7. BM I\>40 kg/m2
• • 8. Uncontrolled diabetes with HbA1C\>9%. (Subjects with controlled diabetes must be under care of diabetologist with treatment goals consistent with ADA criteria).
• • 9. Unstable cardiac disorders within the past 6 months including angina, abnormal ECG, history of cardiac arrest, surgery and/or other interventional procedure.
• • 10. Unstable pulmonary disorders within the past 6 months including dyspnea on exertion, chronic productive cough, pneumonia, hemoptysis, asthma requiring nebulized therapy.
• • 11. Active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.
• • 12. Known to be colonization with either methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.
• • 13. Immunocompromised subjects or subjects receiving immunosuppressive agents.
• • 14. Any history of alcohol and/or drug abuse.
• • 15. Documented history of, or positive result of HIV, Hepatitis B or C, or any infectious disease. External signs, sequelae, or positive serology of sexually transmitted disease (including HPV). Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study.
• • 16. Concurrent participation in any other clinical investigation during the period of this investigation. Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study.
• • 17. Any circumstance in which the investigator deems participation in the study is not in the subject's best interest.
• • 18. Inability to participate in all necessary study activities due to physical or mental limitations.
• • 19. Inability or unwillingness to return for all required follow-up visits, for instance life expectancy \< 1 year, or subject who knows they will be moving out of the country and unable to return for follow-up visits.
• • 20. Inability or unwillingness to sign informed consent.
• • 21. Patients requiring concomitant use of or treatment with immunosuppressive agents
• • 22. Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease).